OSHKOSH CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that OSHKOSH CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 30, 2018 | $2.06B | Nov 20, 2018 |
| FY2018 | Jun 30, 2018 | $2.18B | Nov 20, 2018 |
| FY2018 | Mar 31, 2018 | $1.89B | Nov 20, 2018 |
| FY2018 | Dec 31, 2017 | $1.59B | Nov 20, 2018 |
| FY2018 | Sep 30, 2017 | $1.96B | Nov 20, 2018 |
| FY2018 | Jun 30, 2017 | $2.04B | Nov 20, 2018 |
| FY2018 | Mar 31, 2017 | $1.62B | Nov 20, 2018 |
| FY2018 | Dec 31, 2016 | $1.21B | Nov 20, 2018 |
| FY2018 | Sep 30, 2016 | $6.28B | Nov 20, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.42B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $10.73B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $9.66B | Feb 17, 2026 |
| FY2022 | Dec 31, 2022 | $2.20B | Feb 21, 2023 |
| FY2022 | Sep 30, 2022 | $2.07B | Feb 21, 2023 |
| FY2022 | Jun 30, 2022 | $2.07B | Feb 21, 2023 |
| FY2022 | Mar 31, 2022 | $1.95B | Feb 21, 2023 |
| FY2023 | Dec 31, 2021 | $1.79B | Feb 29, 2024 |
| FY2022 | Sep 30, 2021 | $2.06B | Feb 21, 2023 |
| FY2022 | Jun 30, 2021 | $2.21B | Feb 21, 2023 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $1.96B | Nov 21, 2017 |
| FY2017 | Jun 30, 2017 | $2.04B | Nov 21, 2017 |
| FY2017 | Mar 31, 2017 | $1.62B | Nov 21, 2017 |
| FY2017 | Dec 31, 2016 | $1.21B | Nov 21, 2017 |
| FY2017 | Sep 30, 2016 | $1.76B | Nov 21, 2017 |
| FY2017 | Jun 30, 2016 | $1.75B | Nov 21, 2017 |
| FY2017 | Mar 31, 2016 | $1.52B | Nov 21, 2017 |
| FY2017 | Dec 31, 2015 | $1.25B | Nov 21, 2017 |
| FY2016 | Sep 30, 2015 | $1.58B | Nov 22, 2016 |
| FY2016 | Jun 30, 2015 | $1.61B | Nov 22, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.82B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.97B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.68B | Feb 17, 2026 |
| FY2022 | Dec 31, 2022 | $315.00M | Feb 21, 2023 |
| FY2022 | Sep 30, 2022 | $288.60M | Feb 21, 2023 |
| FY2022 | Jun 30, 2022 | $247.00M | Feb 21, 2023 |
| FY2022 | Mar 31, 2022 | $203.80M | Feb 21, 2023 |
| FY2023 | Dec 31, 2021 | $195.30M | Feb 29, 2024 |
| FY2022 | Sep 30, 2021 | $308.70M | Feb 21, 2023 |
| FY2022 | Jun 30, 2021 | $394.10M | Feb 21, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Sep 30, 2015 | $229.50M | Nov 13, 2015 |
| FY2015 | Sep 30, 2014 | $309.30M | Nov 13, 2015 |
| FY2015 | Sep 30, 2013 | $318.00M | Nov 13, 2015 |
| FY2014 | Sep 30, 2012 | $230.80M | Nov 13, 2014 |
| FY2013 | Sep 30, 2011 | $273.40M | Nov 13, 2013 |
| FY2012 | Sep 30, 2010 | $790.00M | Nov 19, 2012 |
| FY2011 | Sep 30, 2009 | ($1.10B) | Nov 16, 2011 |
| FY2010 | Sep 30, 2008 | $79.30M | Nov 18, 2010 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $939.50M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.01B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $837.60M | Feb 17, 2026 |
| FY2022 | Dec 31, 2022 | $147.00M | Feb 21, 2023 |
| FY2022 | Sep 30, 2022 | $117.20M | Feb 21, 2023 |
| FY2022 | Jun 30, 2022 | $76.30M | Feb 21, 2023 |
| FY2022 | Mar 31, 2022 | $31.80M | Feb 21, 2023 |
| FY2023 | Dec 31, 2021 | $41.60M | Feb 29, 2024 |
| FY2022 | Sep 30, 2021 | $134.40M | Feb 21, 2023 |
| FY2022 | Jun 30, 2021 | $213.30M | Feb 21, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $173.70M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $169.10M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $133.60M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $113.40M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $25.60M | Feb 29, 2024 |
| FY2023 | Sep 30, 2021 | $103.10M | Feb 29, 2024 |
| FY2022 | Sep 30, 2020 | $103.90M | Feb 21, 2023 |
| FY2021 | Sep 30, 2019 | $99.00M | Nov 16, 2021 |
| FY2020 | Sep 30, 2018 | $99.30M | Nov 18, 2020 |
| FY2019 | Sep 30, 2017 | $98.00M | Nov 19, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $818.70M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $852.40M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $810.40M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $662.80M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $150.90M | Feb 29, 2024 |
| FY2023 | Sep 30, 2021 | $666.50M | Feb 29, 2024 |
| FY2022 | Sep 30, 2020 | $620.60M | Feb 21, 2023 |
| FY2021 | Sep 30, 2019 | $683.50M | Nov 16, 2021 |
| FY2020 | Sep 30, 2018 | $664.30M | Nov 18, 2020 |
| FY2019 | Sep 30, 2017 | $664.70M | Nov 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $783.40M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $550.10M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $599.60M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $601.30M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($163.10M) | Feb 29, 2024 |
| FY2023 | Sep 30, 2021 | $1.22B | Feb 29, 2024 |
| FY2022 | Sep 30, 2020 | $327.30M | Feb 21, 2023 |
| FY2021 | Sep 30, 2019 | $568.30M | Nov 16, 2021 |
| FY2020 | Sep 30, 2018 | $436.30M | Nov 18, 2020 |
| FY2019 | Sep 30, 2017 | $246.50M | Nov 19, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $165.40M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $281.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $325.30M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $269.50M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $39.40M | Feb 29, 2024 |
| FY2023 | Sep 30, 2021 | $104.40M | Feb 29, 2024 |
| FY2022 | Sep 30, 2020 | $112.30M | Feb 21, 2023 |
| FY2021 | Sep 30, 2019 | $147.60M | Nov 16, 2021 |
| FY2020 | Sep 30, 2018 | $95.30M | Nov 18, 2020 |
| FY2019 | Sep 30, 2017 | $85.80M | Nov 19, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.07B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $9.42B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $9.13B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $7.73B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $6.85B | Feb 21, 2023 |
| FY2022 | Sep 30, 2021 | $7.04B | Feb 21, 2023 |
| FY2021 | Sep 30, 2020 | $5.82B | Nov 16, 2021 |
| FY2020 | Sep 30, 2019 | $5.57B | Nov 18, 2020 |
| FY2019 | Sep 30, 2018 | $5.29B | Nov 19, 2019 |
| FY2018 | Sep 30, 2017 | $5.10B | Nov 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.53B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $4.15B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $3.71B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $3.19B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $3.20B | Feb 21, 2023 |
| FY2022 | Sep 30, 2021 | $3.36B | Feb 21, 2023 |
| FY2021 | Sep 30, 2020 | $2.85B | Nov 16, 2021 |
| FY2020 | Sep 30, 2019 | $2.60B | Nov 18, 2020 |
| FY2019 | Sep 30, 2018 | $2.51B | Nov 19, 2019 |
| FY2018 | Sep 30, 2017 | $2.31B | Nov 20, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.45B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.41B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.42B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $1.04B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.05B | Feb 29, 2024 |
| FY2022 | Sep 30, 2021 | $1.05B | Feb 21, 2023 |
| FY2022 | Sep 30, 2020 | $1.01B | Feb 21, 2023 |
| FY2021 | Sep 30, 2019 | $995.70M | Nov 16, 2021 |
| FY2020 | Sep 30, 2018 | $1.01B | Nov 18, 2020 |
| FY2019 | Sep 30, 2017 | $1.01B | Nov 19, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.88B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $4.37B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $3.81B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $3.32B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $3.24B | Feb 21, 2023 |
| FY2022 | Sep 30, 2021 | $3.24B | Feb 21, 2023 |
| FY2021 | Sep 30, 2020 | $2.75B | Nov 16, 2021 |
| FY2022 | Oct 1, 2019 | $76.60M | Feb 21, 2023 |
| FY2020 | Sep 30, 2019 | $2.51B | Nov 18, 2020 |
| FY2019 | Sep 30, 2018 | $2.01B | Nov 19, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $479.80M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $204.90M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $125.40M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $805.90M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $995.70M | Feb 21, 2023 |
| FY2022 | Sep 30, 2021 | $1.38B | Feb 21, 2023 |
| FY2021 | Sep 30, 2020 | $582.90M | Nov 16, 2021 |
| FY2020 | Sep 30, 2019 | $448.40M | Nov 18, 2020 |
| FY2019 | Sep 30, 2018 | $454.60M | Nov 19, 2019 |
| FY2018 | Sep 30, 2017 | $447.00M | Nov 20, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $597.50M | Feb 29, 2024 |
| FY2023 | Dec 31, 2022 | $595.00M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $819.00M | Feb 21, 2023 |
| FY2022 | Sep 30, 2021 | $818.80M | Feb 21, 2023 |
| FY2021 | Sep 30, 2020 | $817.90M | Nov 16, 2021 |
| FY2020 | Sep 30, 2019 | $819.00M | Nov 18, 2020 |
| FY2019 | Sep 30, 2018 | $818.00M | Nov 19, 2019 |
| FY2018 | Sep 30, 2017 | $827.90M | Nov 20, 2018 |
| FY2017 | Sep 30, 2016 | $846.20M | Nov 21, 2017 |
| FY2016 | Sep 30, 2015 | $864.30M | Nov 22, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 1 | Feb 21, 2023 |
| FY2022 | Sep 30, 2022 | 1 | Feb 21, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Feb 21, 2023 |
| FY2022 | Sep 30, 2021 | 1 | Feb 21, 2023 |
| FY2022 | Jun 30, 2021 | 3 | Feb 21, 2023 |
| FY2022 | Mar 31, 2021 | 1 | Feb 21, 2023 |
| FY2022 | Dec 31, 2020 | 1 | Feb 21, 2023 |
| FY2020 | Sep 30, 2020 | 1 | Nov 18, 2020 |
| FY2020 | Jun 30, 2020 | 1 | Nov 18, 2020 |
| FY2020 | Mar 31, 2020 | 1 | Nov 18, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 1 | Feb 21, 2023 |
| FY2022 | Sep 30, 2022 | 1 | Feb 21, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Feb 21, 2023 |
| FY2022 | Sep 30, 2021 | 1 | Feb 21, 2023 |
| FY2022 | Jun 30, 2021 | 3 | Feb 21, 2023 |
| FY2022 | Mar 31, 2021 | 1 | Feb 21, 2023 |
| FY2022 | Dec 31, 2020 | 1 | Feb 21, 2023 |
| FY2020 | Sep 30, 2020 | 1 | Nov 18, 2020 |
| FY2020 | Jun 30, 2020 | 1 | Nov 18, 2020 |
| FY2020 | Mar 31, 2020 | 0 | Nov 18, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 62.59M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 64.60M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 65.47M | Feb 17, 2026 |
| FY2025 | Dec 31, 2022 | 65.47M | Feb 17, 2026 |
| FY2024 | Dec 31, 2021 | 66.81M | Feb 20, 2025 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Sep 30, 2009 | $14.90M | Nov 18, 2010 |
| FY2010 | Sep 30, 2008 | $29.80M | Nov 18, 2010 |